Encorafenib plus binimetinib: an embarrassment of riches
Mené dans 28 pays sur 1 345 patients atteints d'un mélanome présentant une mutation BRAF, cet essai de phase III compare l'efficacité, du point de vue de la survie globale, et la toxicité du vémurafénib (191 patients), de l'encorafénib (194 patients) et d'un traitement combinant encorafénib et
Treatment of advanced BRAF-mutant cutaneous melanoma has undergone several breakthroughs, not only in terms of new therapeutic strategies but also in the number of drugs available. The BRAF–MEK inhibitor combinations vemurafenib plus cobimetinib and dabrafenib plus trametinib have been shown to improve overall survival along with pembrolizumab and nivolumab in monotherapy and when combined with ipilimumab. 1
Now, another treatment option can be added to the list: encorafenib plus binimetinib.
The Lancet Oncology , commentaire, 2017